Literature DB >> 29518526

Laparoscopic Common Bile Duct Exploration for Choledocholithiasis: Analysis of Practice Patterns of Intermountain HealthCare.

Daniel Gilsdorf1, Jake Henrichsen2, Katie Liljestrand2, Allison Staheli2, Griffin Olsen2, Prem Narayanan2, Mark Ott2, David S Morris3, Raymond Price2.   

Abstract

BACKGROUND: The ideal management of common bile duct (CBD) stones remains controversial, whether with single-stage management using laparoscopic CBD exploration (LCBDE) during laparoscopic cholecystectomy, or with 2-stage management using preoperative or postoperative ERCP. We wished to elucidate the practice patterns within our health system, which includes both large urban referral centers and small rural critical access hospitals. STUDY
DESIGN: We conducted a retrospective data analysis from our 22-hospital, not-for-profit, integrated healthcare system. All patients with a diagnosis of choledocholithiasis who underwent laparoscopic cholecystectomy (LC) and either ERCP or LCBDE for duct clearance between 2008 and 2013 were included. Demographic data, along with disease-specific characteristics and outcomes, were collected and compared.
RESULTS: During the study period, 37,301 patients underwent LC. Of these, 1,961 (5.3%) met inclusion criteria. Single-stage management with LC+LCBDE was performed in 28% of patients, and the remaining 72% underwent 2-stage management with ERCP (73% postoperative ERCP, 27% preoperative). Mean total number of procedures was lowest in the LC+LCBDE group vs the post-cholecystectomy ERCP group vs the preoperative ERCP group (mean 1.4 vs 2.1 vs 2.3; p < 0.05). Hospital charges were also lower in the LC+LCBDE group vs post-cholecystectomy ERCP vs preoperative ERCP groups ($9,000 vs $10,800 vs $14,200; p < 0.05). Single-stage vs two-stage management varied greatly between hospitals (from 0% to 93%).
CONCLUSIONS: Single-stage management of CBD stones resulted in the fewest procedures and lower hospital charges without an increase in complications. Single-stage management (LC+LCBDE) of CBD stones is underused and can offer better value in today's cost-constrained environment.
Copyright © 2018 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29518526     DOI: 10.1016/j.jamcollsurg.2018.02.008

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

1.  Contemporary management of concomitant gallstones and common bile duct stones: a survey of Spanish surgeons.

Authors:  Rosa Jorba; Mihai C Pavel; Erik Llàcer-Millán; Laia Estalella; Mar Achalandabaso; Elisabet Julià-Verdaguer; Esther Nve; Erlinda D Padilla-Zegarra; Josep M Badia; Donal B O'Connor; Robert Memba
Journal:  Surg Endosc       Date:  2020-09-23       Impact factor: 4.584

2.  T-Tube Use After Laparoscopic Common Bile Duct Exploration.

Authors:  Cuinan Jiang; Xiuhao Zhao; Shi Cheng
Journal:  JSLS       Date:  2019 Jan-Mar       Impact factor: 2.172

3.  Safety and efficacy of emergency laparoscopic common bile duct exploration in elderly patients with complicated acute cholangitis.

Authors:  Baoxing Jia; Zhe Jin; Wei Han; Yahui Liu
Journal:  Surg Endosc       Date:  2019-06-17       Impact factor: 4.584

4.  Comparison on the Efficacy of Three Duct Closure Methods after Laparoscopic Common Bile Duct Exploration for Choledocholithiasis.

Authors:  Ancheng Qin; Jianwu Wu; Zhiming Qiao; Min Zhai; Yijie Lu; Bo Huang; Xinwei Jiang; Xingsheng Lu
Journal:  Med Sci Monit       Date:  2019-12-20

5.  3D Laparoscopic common bile duct exploration with primary repair by absorbable barbed suture is safe and feasible.

Authors:  Yen Pin Tan; Cheryl Lim; Sameer P Junnarkar; Cheong Wei Terence Huey; Vishalkumar G Shelat
Journal:  J Clin Transl Res       Date:  2021-07-16

6.  Routine intraoperative cholangiography during laparoscopic cholecystectomy: application of the 2016 WSES guidelines for predicting choledocholithiasis.

Authors:  Hui-Ying Lai; Kuei-Yen Tsai; Hsin-An Chen
Journal:  Surg Endosc       Date:  2021-02-01       Impact factor: 4.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.